Toll Biotech

Explore the latest insights on Toll Biotech and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Toll Biotech’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Company Drug

Betta Pharmaceuticals Secures FDA IND Approval for BPI‑572270 Capsules – Novel Pan‑RAS “Non‑Degradative Molecular Glue” Inhibitor Advances into U.S. Clinical Trials

Betta Pharmaceuticals Co., Ltd. (SHE: 300558) announced that its wholly‑owned subsidiary, Hangzhou Jingyao Biotechnology Co., Ltd., has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration…

October 8, 2026

Allist’s Firmonertinib Misses Primary PFS Endpoint in Phase 3 FURVENT Trial – 60% Response Rate and OS Trend Keep EGFR Exon 20 Insertion NSCLC Program Alive

October 8, 2026

Danatlas Pharmaceuticals Doses First Patient in Phase II Trial of DAT‑2645 – Novel Targeted Therapy for BRCA‑Mutant, HRD‑Positive Ovarian Cancer

October 6, 2026

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.

Explore Now